Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced NSCLC
Roche announced positive data from the Phase III IMpower110 study evaluating Tecentriq® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced NSCLC without ALK or EGFR mutations. September 12, 2019